カテゴリー： QYResearch, 世界, 医療/バイオ

世界の移植片対宿主病治療市場インサイト及び予測（エタネルセプト、モノクローナル抗体、サリドマイド、チロシンキナーゼ阻害剤、mTOR阻害剤）

◆英語タイトル：Global Graft Versus Host Disease Treatment Market Insights, Forecast to 2028

QYResearchが発行した調査報告書（QY22JL3465）◆商品コード：QY22JL3465
◆発行会社（リサーチ会社）：QYResearch
◆発行日：2022年7月（※2025年版があります。お問い合わせください。）
◆ページ数：115
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後3営業日）
◆調査対象地域：グローバル
◆産業分野：医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD4,900 ⇒換算￥744,800見積依頼/購入/質問フォーム
Multi User（5名様閲覧用）USD7,350 ⇒換算￥1,117,200見積依頼/購入/質問フォーム
Enterprise License（同一法人内共有可）USD9,800 ⇒換算￥1,489,600見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

COVID-19のパンデミックにより、移植片対宿主病治療のグローバル市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に移植片対宿主病治療の世界市場のxxx％を占める「エタネルセプト」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx％CAGRで成長すると予測されています。一方、「急性GVHD」セグメントは、この予測期間を通じてxxx％のCAGRに変更されます。
移植片対宿主病治療の中国市場規模は2021年にUS$xxxと分析されており、米国とヨーロッパの市場規模はそれぞれUS$xxxとUS$xxxです。米国の割合は2021年にxxx％であり、中国とヨーロッパはそれぞれxxx％とxxx％です。中国の割合は2028年にxxx％に達し、対象期間を通じてxxx％のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx％、xxx％、xxx％になる見通しです。ヨーロッパの移植片対宿主病治療市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx％になる見通しです。

移植片対宿主病治療のグローバル主要企業には、AbbVie Inc.、Acrofan、Astellas Pharma Inc.、Bristol-Myers Squibb Company、ElsaLys Biotech SA、F. Hoffmann-La Roche AG、Johnson & Johnson、Mallinckrodft PLC、Merck & Co., Inc.、Mesoblast Limited、Neovii Biotech GmbH、Novartis AG、Ocugen, Inc.、Pfizer Inc、Pluristem Therapeutics Inc.、Samedan Ltd、Sanofi SA、Soligenix, Inc.などがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。

移植片対宿主病治療市場は、種類と用途によって区分されます。世界の移植片対宿主病治療市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。

【種類別セグメント】
エタネルセプト、モノクローナル抗体、サリドマイド、チロシンキナーゼ阻害剤、mTOR阻害剤

【用途別セグメント】
急性GVHD、慢性GVHD、予防GVHD

【掲載地域】
北米：アメリカ、カナダ
ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア
中南米：メキシコ、ブラジル、アルゼンチン
中東・アフリカ：トルコ、サウジアラビア、UAE

【目次（一部）】

・調査の範囲
- 移植片対宿主病治療製品概要
- 種類別市場（エタネルセプト、モノクローナル抗体、サリドマイド、チロシンキナーゼ阻害剤、mTOR阻害剤）
- 用途別市場（急性GVHD、慢性GVHD、予防GVHD）
- 調査の目的
・エグゼクティブサマリー
- 世界の移植片対宿主病治療販売量予測2017-2028
- 世界の移植片対宿主病治療売上予測2017-2028
- 移植片対宿主病治療の地域別販売量
- 移植片対宿主病治療の地域別売上
- 北米市場
- ヨーロッパ市場
- アジア太平洋市場
- 中南米市場
- 中東・アフリカ市場
・メーカーの競争状況
- 主要メーカー別移植片対宿主病治療販売量
- 主要メーカー別移植片対宿主病治療売上
- 主要メーカー別移植片対宿主病治療価格
- 競争状況の分析
- 企業M&A動向
・種類別市場規模（エタネルセプト、モノクローナル抗体、サリドマイド、チロシンキナーゼ阻害剤、mTOR阻害剤）
- 移植片対宿主病治療の種類別販売量
- 移植片対宿主病治療の種類別売上
- 移植片対宿主病治療の種類別価格
・用途別市場規模（急性GVHD、慢性GVHD、予防GVHD）
- 移植片対宿主病治療の用途別販売量
- 移植片対宿主病治療の用途別売上
- 移植片対宿主病治療の用途別価格
・北米市場
- 北米の移植片対宿主病治療市場規模（種類別、用途別）
- 主要国別の移植片対宿主病治療市場規模（アメリカ、カナダ）
・ヨーロッパ市場
- ヨーロッパの移植片対宿主病治療市場規模（種類別、用途別）
- 主要国別の移植片対宿主病治療市場規模（ドイツ、フランス、イギリス、イタリア、ロシア）
・アジア太平洋市場
- アジア太平洋の移植片対宿主病治療市場規模（種類別、用途別）
- 主要国別の移植片対宿主病治療市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア）
・中南米市場
- 中南米の移植片対宿主病治療市場規模（種類別、用途別）
- 主要国別の移植片対宿主病治療市場規模（メキシコ、ブラジル、アルゼンチン）
・中東・アフリカ市場
- 中東・アフリカの移植片対宿主病治療市場規模（種類別、用途別）
- 主要国別の移植片対宿主病治療市場規模（トルコ、サウジアラビア）
・企業情報
AbbVie Inc.、Acrofan、Astellas Pharma Inc.、Bristol-Myers Squibb Company、ElsaLys Biotech SA、F. Hoffmann-La Roche AG、Johnson & Johnson、Mallinckrodft PLC、Merck & Co., Inc.、Mesoblast Limited、Neovii Biotech GmbH、Novartis AG、Ocugen, Inc.、Pfizer Inc、Pluristem Therapeutics Inc.、Samedan Ltd、Sanofi SA、Soligenix, Inc.
・産業チェーン及び販売チャネル分析
- 移植片対宿主病治療の産業チェーン分析
- 移植片対宿主病治療の原材料
- 移植片対宿主病治療の生産プロセス
- 移植片対宿主病治療の販売及びマーケティング
- 移植片対宿主病治療の主要顧客
・マーケットドライバー、機会、課題、リスク要因分析
- 移植片対宿主病治療の産業動向
- 移植片対宿主病治療のマーケットドライバー
- 移植片対宿主病治療の課題
- 移植片対宿主病治療の阻害要因
・主な調査結果

Market Analysis and Insights: Global Graft Versus Host Disease Treatment Market
The global Graft Versus Host Disease Treatment market size is projected to reach US$ million by 2028, from US$ million in 2021, at a CAGR of % during 2022-2028.
Fully considering the economic change by this health crisis, Etanercept accounting for % of the Graft Versus Host Disease Treatment global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Acute GVHD segment is altered to an % CAGR throughout this forecast period.
China Graft Versus Host Disease Treatment market size is valued at US$ million in 2021, while the North America and Europe Graft Versus Host Disease Treatment are US$ million and US$ million, severally. The proportion of the North America is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Graft Versus Host Disease Treatment landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Graft Versus Host Disease Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Graft Versus Host Disease Treatment market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Graft Versus Host Disease Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Graft Versus Host Disease Treatment market.
Global Graft Versus Host Disease Treatment Scope and Market Size
Graft Versus Host Disease Treatment market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Graft Versus Host Disease Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Etanercept
Monoclonal Antibodies
Thalidomide
Tyrosine Kinase Inhibitors
mTOR Inhibitors
Segment by Application
Acute GVHD
Chronic GVHD
Prophylaxis GVHD
By Company
AbbVie Inc.
Acrofan
Astellas Pharma Inc.
Bristol-Myers Squibb Company
ElsaLys Biotech SA
F. Hoffmann-La Roche AG
Johnson & Johnson
Mallinckrodft PLC
Merck & Co., Inc.
Mesoblast Limited
Neovii Biotech GmbH
Novartis AG
Ocugen, Inc.
Pfizer Inc
Pluristem Therapeutics Inc.
Samedan Ltd
Sanofi SA
Soligenix, Inc.
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

❖ レポートの目次 ❖

1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Graft Versus Host Disease Treatment Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Etanercept
1.2.3 Monoclonal Antibodies
1.2.4 Thalidomide
1.2.5 Tyrosine Kinase Inhibitors
1.2.6 mTOR Inhibitors
1.3 Market by Application
1.3.1 Global Graft Versus Host Disease Treatment Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Acute GVHD
1.3.3 Chronic GVHD
1.3.4 Prophylaxis GVHD
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Graft Versus Host Disease Treatment Market Perspective (2017-2028)
2.2 Graft Versus Host Disease Treatment Growth Trends by Region
2.2.1 Graft Versus Host Disease Treatment Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Graft Versus Host Disease Treatment Historic Market Size by Region (2017-2022)
2.2.3 Graft Versus Host Disease Treatment Forecasted Market Size by Region (2023-2028)
2.3 Graft Versus Host Disease Treatment Market Dynamics
2.3.1 Graft Versus Host Disease Treatment Industry Trends
2.3.2 Graft Versus Host Disease Treatment Market Drivers
2.3.3 Graft Versus Host Disease Treatment Market Challenges
2.3.4 Graft Versus Host Disease Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Graft Versus Host Disease Treatment Players by Revenue
3.1.1 Global Top Graft Versus Host Disease Treatment Players by Revenue (2017-2022)
3.1.2 Global Graft Versus Host Disease Treatment Revenue Market Share by Players (2017-2022)
3.2 Global Graft Versus Host Disease Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Graft Versus Host Disease Treatment Revenue
3.4 Global Graft Versus Host Disease Treatment Market Concentration Ratio
3.4.1 Global Graft Versus Host Disease Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Graft Versus Host Disease Treatment Revenue in 2021
3.5 Graft Versus Host Disease Treatment Key Players Head office and Area Served
3.6 Key Players Graft Versus Host Disease Treatment Product Solution and Service
3.7 Date of Enter into Graft Versus Host Disease Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Graft Versus Host Disease Treatment Breakdown Data by Type
4.1 Global Graft Versus Host Disease Treatment Historic Market Size by Type (2017-2022)
4.2 Global Graft Versus Host Disease Treatment Forecasted Market Size by Type (2023-2028)
5 Graft Versus Host Disease Treatment Breakdown Data by Application
5.1 Global Graft Versus Host Disease Treatment Historic Market Size by Application (2017-2022)
5.2 Global Graft Versus Host Disease Treatment Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Graft Versus Host Disease Treatment Market Size (2017-2028)
6.2 North America Graft Versus Host Disease Treatment Market Size by Type
6.2.1 North America Graft Versus Host Disease Treatment Market Size by Type (2017-2022)
6.2.2 North America Graft Versus Host Disease Treatment Market Size by Type (2023-2028)
6.2.3 North America Graft Versus Host Disease Treatment Market Share by Type (2017-2028)
6.3 North America Graft Versus Host Disease Treatment Market Size by Application
6.3.1 North America Graft Versus Host Disease Treatment Market Size by Application (2017-2022)
6.3.2 North America Graft Versus Host Disease Treatment Market Size by Application (2023-2028)
6.3.3 North America Graft Versus Host Disease Treatment Market Share by Application (2017-2028)
6.4 North America Graft Versus Host Disease Treatment Market Size by Country
6.4.1 North America Graft Versus Host Disease Treatment Market Size by Country (2017-2022)
6.4.2 North America Graft Versus Host Disease Treatment Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Graft Versus Host Disease Treatment Market Size (2017-2028)
7.2 Europe Graft Versus Host Disease Treatment Market Size by Type
7.2.1 Europe Graft Versus Host Disease Treatment Market Size by Type (2017-2022)
7.2.2 Europe Graft Versus Host Disease Treatment Market Size by Type (2023-2028)
7.2.3 Europe Graft Versus Host Disease Treatment Market Share by Type (2017-2028)
7.3 Europe Graft Versus Host Disease Treatment Market Size by Application
7.3.1 Europe Graft Versus Host Disease Treatment Market Size by Application (2017-2022)
7.3.2 Europe Graft Versus Host Disease Treatment Market Size by Application (2023-2028)
7.3.3 Europe Graft Versus Host Disease Treatment Market Share by Application (2017-2028)
7.4 Europe Graft Versus Host Disease Treatment Market Size by Country
7.4.1 Europe Graft Versus Host Disease Treatment Market Size by Country (2017-2022)
7.4.2 Europe Graft Versus Host Disease Treatment Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Graft Versus Host Disease Treatment Market Size (2017-2028)
8.2 Asia-Pacific Graft Versus Host Disease Treatment Market Size by Type
8.2.1 Asia-Pacific Graft Versus Host Disease Treatment Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Graft Versus Host Disease Treatment Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Graft Versus Host Disease Treatment Market Share by Type (2017-2028)
8.3 Asia-Pacific Graft Versus Host Disease Treatment Market Size by Application
8.3.1 Asia-Pacific Graft Versus Host Disease Treatment Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Graft Versus Host Disease Treatment Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Graft Versus Host Disease Treatment Market Share by Application (2017-2028)
8.4 Asia-Pacific Graft Versus Host Disease Treatment Market Size by Region
8.4.1 Asia-Pacific Graft Versus Host Disease Treatment Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Graft Versus Host Disease Treatment Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Graft Versus Host Disease Treatment Market Size (2017-2028)
9.2 Latin America Graft Versus Host Disease Treatment Market Size by Type
9.2.1 Latin America Graft Versus Host Disease Treatment Market Size by Type (2017-2022)
9.2.2 Latin America Graft Versus Host Disease Treatment Market Size by Type (2023-2028)
9.2.3 Latin America Graft Versus Host Disease Treatment Market Share by Type (2017-2028)
9.3 Latin America Graft Versus Host Disease Treatment Market Size by Application
9.3.1 Latin America Graft Versus Host Disease Treatment Market Size by Application (2017-2022)
9.3.2 Latin America Graft Versus Host Disease Treatment Market Size by Application (2023-2028)
9.3.3 Latin America Graft Versus Host Disease Treatment Market Share by Application (2017-2028)
9.4 Latin America Graft Versus Host Disease Treatment Market Size by Country
9.4.1 Latin America Graft Versus Host Disease Treatment Market Size by Country (2017-2022)
9.4.2 Latin America Graft Versus Host Disease Treatment Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Graft Versus Host Disease Treatment Market Size (2017-2028)
10.2 Middle East & Africa Graft Versus Host Disease Treatment Market Size by Type
10.2.1 Middle East & Africa Graft Versus Host Disease Treatment Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Graft Versus Host Disease Treatment Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Graft Versus Host Disease Treatment Market Share by Type (2017-2028)
10.3 Middle East & Africa Graft Versus Host Disease Treatment Market Size by Application
10.3.1 Middle East & Africa Graft Versus Host Disease Treatment Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Graft Versus Host Disease Treatment Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Graft Versus Host Disease Treatment Market Share by Application (2017-2028)
10.4 Middle East & Africa Graft Versus Host Disease Treatment Market Size by Country
10.4.1 Middle East & Africa Graft Versus Host Disease Treatment Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Graft Versus Host Disease Treatment Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 AbbVie Inc.
11.1.1 AbbVie Inc. Company Details
11.1.2 AbbVie Inc. Business Overview
11.1.3 AbbVie Inc. Graft Versus Host Disease Treatment Introduction
11.1.4 AbbVie Inc. Revenue in Graft Versus Host Disease Treatment Business (2017-2022)
11.1.5 AbbVie Inc. Recent Developments
11.2 Acrofan
11.2.1 Acrofan Company Details
11.2.2 Acrofan Business Overview
11.2.3 Acrofan Graft Versus Host Disease Treatment Introduction
11.2.4 Acrofan Revenue in Graft Versus Host Disease Treatment Business (2017-2022)
11.2.5 Acrofan Recent Developments
11.3 Astellas Pharma Inc.
11.3.1 Astellas Pharma Inc. Company Details
11.3.2 Astellas Pharma Inc. Business Overview
11.3.3 Astellas Pharma Inc. Graft Versus Host Disease Treatment Introduction
11.3.4 Astellas Pharma Inc. Revenue in Graft Versus Host Disease Treatment Business (2017-2022)
11.3.5 Astellas Pharma Inc. Recent Developments
11.4 Bristol-Myers Squibb Company
11.4.1 Bristol-Myers Squibb Company Company Details
11.4.2 Bristol-Myers Squibb Company Business Overview
11.4.3 Bristol-Myers Squibb Company Graft Versus Host Disease Treatment Introduction
11.4.4 Bristol-Myers Squibb Company Revenue in Graft Versus Host Disease Treatment Business (2017-2022)
11.4.5 Bristol-Myers Squibb Company Recent Developments
11.5 ElsaLys Biotech SA
11.5.1 ElsaLys Biotech SA Company Details
11.5.2 ElsaLys Biotech SA Business Overview
11.5.3 ElsaLys Biotech SA Graft Versus Host Disease Treatment Introduction
11.5.4 ElsaLys Biotech SA Revenue in Graft Versus Host Disease Treatment Business (2017-2022)
11.5.5 ElsaLys Biotech SA Recent Developments
11.6 F. Hoffmann-La Roche AG
11.6.1 F. Hoffmann-La Roche AG Company Details
11.6.2 F. Hoffmann-La Roche AG Business Overview
11.6.3 F. Hoffmann-La Roche AG Graft Versus Host Disease Treatment Introduction
11.6.4 F. Hoffmann-La Roche AG Revenue in Graft Versus Host Disease Treatment Business (2017-2022)
11.6.5 F. Hoffmann-La Roche AG Recent Developments
11.7 Johnson & Johnson
11.7.1 Johnson & Johnson Company Details
11.7.2 Johnson & Johnson Business Overview
11.7.3 Johnson & Johnson Graft Versus Host Disease Treatment Introduction
11.7.4 Johnson & Johnson Revenue in Graft Versus Host Disease Treatment Business (2017-2022)
11.7.5 Johnson & Johnson Recent Developments
11.8 Mallinckrodft PLC
11.8.1 Mallinckrodft PLC Company Details
11.8.2 Mallinckrodft PLC Business Overview
11.8.3 Mallinckrodft PLC Graft Versus Host Disease Treatment Introduction
11.8.4 Mallinckrodft PLC Revenue in Graft Versus Host Disease Treatment Business (2017-2022)
11.8.5 Mallinckrodft PLC Recent Developments
11.9 Merck & Co., Inc.
11.9.1 Merck & Co., Inc. Company Details
11.9.2 Merck & Co., Inc. Business Overview
11.9.3 Merck & Co., Inc. Graft Versus Host Disease Treatment Introduction
11.9.4 Merck & Co., Inc. Revenue in Graft Versus Host Disease Treatment Business (2017-2022)
11.9.5 Merck & Co., Inc. Recent Developments
11.10 Mesoblast Limited
11.10.1 Mesoblast Limited Company Details
11.10.2 Mesoblast Limited Business Overview
11.10.3 Mesoblast Limited Graft Versus Host Disease Treatment Introduction
11.10.4 Mesoblast Limited Revenue in Graft Versus Host Disease Treatment Business (2017-2022)
11.10.5 Mesoblast Limited Recent Developments
11.11 Neovii Biotech GmbH
11.11.1 Neovii Biotech GmbH Company Details
11.11.2 Neovii Biotech GmbH Business Overview
11.11.3 Neovii Biotech GmbH Graft Versus Host Disease Treatment Introduction
11.11.4 Neovii Biotech GmbH Revenue in Graft Versus Host Disease Treatment Business (2017-2022)
11.11.5 Neovii Biotech GmbH Recent Developments
11.12 Novartis AG
11.12.1 Novartis AG Company Details
11.12.2 Novartis AG Business Overview
11.12.3 Novartis AG Graft Versus Host Disease Treatment Introduction
11.12.4 Novartis AG Revenue in Graft Versus Host Disease Treatment Business (2017-2022)
11.12.5 Novartis AG Recent Developments
11.13 Ocugen, Inc.
11.13.1 Ocugen, Inc. Company Details
11.13.2 Ocugen, Inc. Business Overview
11.13.3 Ocugen, Inc. Graft Versus Host Disease Treatment Introduction
11.13.4 Ocugen, Inc. Revenue in Graft Versus Host Disease Treatment Business (2017-2022)
11.13.5 Ocugen, Inc. Recent Developments
11.14 Pfizer Inc
11.14.1 Pfizer Inc Company Details
11.14.2 Pfizer Inc Business Overview
11.14.3 Pfizer Inc Graft Versus Host Disease Treatment Introduction
11.14.4 Pfizer Inc Revenue in Graft Versus Host Disease Treatment Business (2017-2022)
11.14.5 Pfizer Inc Recent Developments
11.15 Pluristem Therapeutics Inc.
11.15.1 Pluristem Therapeutics Inc. Company Details
11.15.2 Pluristem Therapeutics Inc. Business Overview
11.15.3 Pluristem Therapeutics Inc. Graft Versus Host Disease Treatment Introduction
11.15.4 Pluristem Therapeutics Inc. Revenue in Graft Versus Host Disease Treatment Business (2017-2022)
11.15.5 Pluristem Therapeutics Inc. Recent Developments
11.16 Samedan Ltd
11.16.1 Samedan Ltd Company Details
11.16.2 Samedan Ltd Business Overview
11.16.3 Samedan Ltd Graft Versus Host Disease Treatment Introduction
11.16.4 Samedan Ltd Revenue in Graft Versus Host Disease Treatment Business (2017-2022)
11.16.5 Samedan Ltd Recent Developments
11.17 Sanofi SA
11.17.1 Sanofi SA Company Details
11.17.2 Sanofi SA Business Overview
11.17.3 Sanofi SA Graft Versus Host Disease Treatment Introduction
11.17.4 Sanofi SA Revenue in Graft Versus Host Disease Treatment Business (2017-2022)
11.17.5 Sanofi SA Recent Developments
11.18 Soligenix, Inc.
11.18.1 Soligenix, Inc. Company Details
11.18.2 Soligenix, Inc. Business Overview
11.18.3 Soligenix, Inc. Graft Versus Host Disease Treatment Introduction
11.18.4 Soligenix, Inc. Revenue in Graft Versus Host Disease Treatment Business (2017-2022)
11.18.5 Soligenix, Inc. Recent Developments
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer

List of Tables
Table 1. Global Graft Versus Host Disease Treatment Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
Table 2. Key Players of Etanercept
Table 3. Key Players of Monoclonal Antibodies
Table 4. Key Players of Thalidomide
Table 5. Key Players of Tyrosine Kinase Inhibitors
Table 6. Key Players of mTOR Inhibitors
Table 7. Global Graft Versus Host Disease Treatment Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
Table 8. Global Graft Versus Host Disease Treatment Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
Table 9. Global Graft Versus Host Disease Treatment Market Size by Region (2017-2022) & (US$ Million)
Table 10. Global Graft Versus Host Disease Treatment Market Share by Region (2017-2022)
Table 11. Global Graft Versus Host Disease Treatment Forecasted Market Size by Region (2023-2028) & (US$ Million)
Table 12. Global Graft Versus Host Disease Treatment Market Share by Region (2023-2028)
Table 13. Graft Versus Host Disease Treatment Market Trends
Table 14. Graft Versus Host Disease Treatment Market Drivers
Table 15. Graft Versus Host Disease Treatment Market Challenges
Table 16. Graft Versus Host Disease Treatment Market Restraints
Table 17. Global Graft Versus Host Disease Treatment Revenue by Players (2017-2022) & (US$ Million)
Table 18. Global Graft Versus Host Disease Treatment Revenue Share by Players (2017-2022)
Table 19. Global Top Graft Versus Host Disease Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Graft Versus Host Disease Treatment as of 2021)
Table 20. Ranking of Global Top Graft Versus Host Disease Treatment Companies by Revenue (US$ Million) in 2021
Table 21. Global 5 Largest Players Market Share by Graft Versus Host Disease Treatment Revenue (CR5 and HHI) & (2017-2022)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Graft Versus Host Disease Treatment Product Solution and Service
Table 24. Date of Enter into Graft Versus Host Disease Treatment Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Graft Versus Host Disease Treatment Market Size by Type (2017-2022) & (US$ Million)
Table 27. Global Graft Versus Host Disease Treatment Revenue Market Share by Type (2017-2022)
Table 28. Global Graft Versus Host Disease Treatment Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 29. Global Graft Versus Host Disease Treatment Revenue Market Share by Type (2023-2028)
Table 30. Global Graft Versus Host Disease Treatment Market Size by Application (2017-2022) & (US$ Million)
Table 31. Global Graft Versus Host Disease Treatment Revenue Share by Application (2017-2022)
Table 32. Global Graft Versus Host Disease Treatment Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 33. Global Graft Versus Host Disease Treatment Revenue Share by Application (2023-2028)
Table 34. North America Graft Versus Host Disease Treatment Market Size by Type (2017-2022) & (US$ Million)
Table 35. North America Graft Versus Host Disease Treatment Market Size by Type (2023-2028) & (US$ Million)
Table 36. North America Graft Versus Host Disease Treatment Market Size by Application (2017-2022) & (US$ Million)
Table 37. North America Graft Versus Host Disease Treatment Market Size by Application (2023-2028) & (US$ Million)
Table 38. North America Graft Versus Host Disease Treatment Market Size by Country (2017-2022) & (US$ Million)
Table 39. North America Graft Versus Host Disease Treatment Market Size by Country (2023-2028) & (US$ Million)
Table 40. Europe Graft Versus Host Disease Treatment Market Size by Type (2017-2022) & (US$ Million)
Table 41. Europe Graft Versus Host Disease Treatment Market Size by Type (2023-2028) & (US$ Million)
Table 42. Europe Graft Versus Host Disease Treatment Market Size by Application (2017-2022) & (US$ Million)
Table 43. Europe Graft Versus Host Disease Treatment Market Size by Application (2023-2028) & (US$ Million)
Table 44. Europe Graft Versus Host Disease Treatment Market Size by Country (2017-2022) & (US$ Million)
Table 45. Europe Graft Versus Host Disease Treatment Market Size by Country (2023-2028) & (US$ Million)
Table 46. Asia Pacific Graft Versus Host Disease Treatment Market Size by Type (2017-2022) & (US$ Million)
Table 47. Asia Pacific Graft Versus Host Disease Treatment Market Size by Type (2023-2028) & (US$ Million)
Table 48. Asia Pacific Graft Versus Host Disease Treatment Market Size by Application (2017-2022) & (US$ Million)
Table 49. Asia Pacific Graft Versus Host Disease Treatment Market Size by Application (2023-2028) & (US$ Million)
Table 50. Asia Pacific Graft Versus Host Disease Treatment Market Size by Region (2017-2022) & (US$ Million)
Table 51. Asia Pacific Graft Versus Host Disease Treatment Market Size by Region (2023-2028) & (US$ Million)
Table 52. Latin America Graft Versus Host Disease Treatment Market Size by Type (2017-2022) & (US$ Million)
Table 53. Latin America Graft Versus Host Disease Treatment Market Size by Type (2023-2028) & (US$ Million)
Table 54. Latin America Graft Versus Host Disease Treatment Market Size by Application (2017-2022) & (US$ Million)
Table 55. Latin America Graft Versus Host Disease Treatment Market Size by Application (2023-2028) & (US$ Million)
Table 56. Latin America Graft Versus Host Disease Treatment Market Size by Country (2017-2022) & (US$ Million)
Table 57. Latin America Graft Versus Host Disease Treatment Market Size by Country (2023-2028) & (US$ Million)
Table 58. Middle East and Africa Graft Versus Host Disease Treatment Market Size by Type (2017-2022) & (US$ Million)
Table 59. Middle East and Africa Graft Versus Host Disease Treatment Market Size by Type (2023-2028) & (US$ Million)
Table 60. Middle East and Africa Graft Versus Host Disease Treatment Market Size by Application (2017-2022) & (US$ Million)
Table 61. Middle East and Africa Graft Versus Host Disease Treatment Market Size by Application (2023-2028) & (US$ Million)
Table 62. Middle East and Africa Graft Versus Host Disease Treatment Market Size by Country (2017-2022) & (US$ Million)
Table 63. Middle East and Africa Graft Versus Host Disease Treatment Market Size by Country (2023-2028) & (US$ Million)
Table 64. AbbVie Inc. Company Details
Table 65. AbbVie Inc. Business Overview
Table 66. AbbVie Inc. Graft Versus Host Disease Treatment Product
Table 67. AbbVie Inc. Revenue in Graft Versus Host Disease Treatment Business (2017-2022) & (US$ Million)
Table 68. AbbVie Inc. Recent Developments
Table 69. Acrofan Company Details
Table 70. Acrofan Business Overview
Table 71. Acrofan Graft Versus Host Disease Treatment Product
Table 72. Acrofan Revenue in Graft Versus Host Disease Treatment Business (2017-2022) & (US$ Million)
Table 73. Acrofan Recent Developments
Table 74. Astellas Pharma Inc. Company Details
Table 75. Astellas Pharma Inc. Business Overview
Table 76. Astellas Pharma Inc. Graft Versus Host Disease Treatment Product
Table 77. Astellas Pharma Inc. Revenue in Graft Versus Host Disease Treatment Business (2017-2022) & (US$ Million)
Table 78. Astellas Pharma Inc. Recent Developments
Table 79. Bristol-Myers Squibb Company Company Details
Table 80. Bristol-Myers Squibb Company Business Overview
Table 81. Bristol-Myers Squibb Company Graft Versus Host Disease Treatment Product
Table 82. Bristol-Myers Squibb Company Revenue in Graft Versus Host Disease Treatment Business (2017-2022) & (US$ Million)
Table 83. Bristol-Myers Squibb Company Recent Developments
Table 84. ElsaLys Biotech SA Company Details
Table 85. ElsaLys Biotech SA Business Overview
Table 86. ElsaLys Biotech SA Graft Versus Host Disease Treatment Product
Table 87. ElsaLys Biotech SA Revenue in Graft Versus Host Disease Treatment Business (2017-2022) & (US$ Million)
Table 88. ElsaLys Biotech SA Recent Developments
Table 89. F. Hoffmann-La Roche AG Company Details
Table 90. F. Hoffmann-La Roche AG Business Overview
Table 91. F. Hoffmann-La Roche AG Graft Versus Host Disease Treatment Product
Table 92. F. Hoffmann-La Roche AG Revenue in Graft Versus Host Disease Treatment Business (2017-2022) & (US$ Million)
Table 93. F. Hoffmann-La Roche AG Recent Developments
Table 94. Johnson & Johnson Company Details
Table 95. Johnson & Johnson Business Overview
Table 96. Johnson & Johnson Graft Versus Host Disease Treatment Product
Table 97. Johnson & Johnson Revenue in Graft Versus Host Disease Treatment Business (2017-2022) & (US$ Million)
Table 98. Johnson & Johnson Recent Developments
Table 99. Mallinckrodft PLC Company Details
Table 100. Mallinckrodft PLC Business Overview
Table 101. Mallinckrodft PLC Graft Versus Host Disease Treatment Product
Table 102. Mallinckrodft PLC Revenue in Graft Versus Host Disease Treatment Business (2017-2022) & (US$ Million)
Table 103. Mallinckrodft PLC Recent Developments
Table 104. Merck & Co., Inc. Company Details
Table 105. Merck & Co., Inc. Business Overview
Table 106. Merck & Co., Inc. Graft Versus Host Disease Treatment Product
Table 107. Merck & Co., Inc. Revenue in Graft Versus Host Disease Treatment Business (2017-2022) & (US$ Million)
Table 108. Merck & Co., Inc. Recent Developments
Table 109. Mesoblast Limited Company Details
Table 110. Mesoblast Limited Business Overview
Table 111. Mesoblast Limited Graft Versus Host Disease Treatment Product
Table 112. Mesoblast Limited Revenue in Graft Versus Host Disease Treatment Business (2017-2022) & (US$ Million)
Table 113. Mesoblast Limited Recent Developments
Table 114. Neovii Biotech GmbH Company Details
Table 115. Neovii Biotech GmbH Business Overview
Table 116. Neovii Biotech GmbH Graft Versus Host Disease Treatment Product
Table 117. Neovii Biotech GmbH Revenue in Graft Versus Host Disease Treatment Business (2017-2022) & (US$ Million)
Table 118. Neovii Biotech GmbH Recent Developments
Table 119. Novartis AG Company Details
Table 120. Novartis AG Business Overview
Table 121. Novartis AG Graft Versus Host Disease Treatment Product
Table 122. Novartis AG Revenue in Graft Versus Host Disease Treatment Business (2017-2022) & (US$ Million)
Table 123. Novartis AG Recent Developments
Table 124. Ocugen, Inc. Company Details
Table 125. Ocugen, Inc. Business Overview
Table 126. Ocugen, Inc. Graft Versus Host Disease Treatment Product
Table 127. Ocugen, Inc. Revenue in Graft Versus Host Disease Treatment Business (2017-2022) & (US$ Million)
Table 128. Ocugen, Inc. Recent Developments
Table 129. Pfizer Inc Company Details
Table 130. Pfizer Inc Business Overview
Table 131. Pfizer Inc Graft Versus Host Disease Treatment Product
Table 132. Pfizer Inc Revenue in Graft Versus Host Disease Treatment Business (2017-2022) & (US$ Million)
Table 133. Pfizer Inc Recent Developments
Table 134. Pluristem Therapeutics Inc. Company Details
Table 135. Pluristem Therapeutics Inc. Business Overview
Table 136. Pluristem Therapeutics Inc. Graft Versus Host Disease Treatment Product
Table 137. Pluristem Therapeutics Inc. Revenue in Graft Versus Host Disease Treatment Business (2017-2022) & (US$ Million)
Table 138. Pluristem Therapeutics Inc. Recent Developments
Table 139. Samedan Ltd Company Details
Table 140. Samedan Ltd Business Overview
Table 141. Samedan Ltd Graft Versus Host Disease Treatment Product
Table 142. Samedan Ltd Revenue in Graft Versus Host Disease Treatment Business (2017-2022) & (US$ Million)
Table 143. Samedan Ltd Recent Developments
Table 144. Sanofi SA Company Details
Table 145. Sanofi SA Business Overview
Table 146. Sanofi SA Graft Versus Host Disease Treatment Product
Table 147. Sanofi SA Revenue in Graft Versus Host Disease Treatment Business (2017-2022) & (US$ Million)
Table 148. Sanofi SA Recent Developments
Table 149. Soligenix, Inc. Company Details
Table 150. Soligenix, Inc. Business Overview
Table 151. Soligenix, Inc. Graft Versus Host Disease Treatment Product
Table 152. Soligenix, Inc. Revenue in Graft Versus Host Disease Treatment Business (2017-2022) & (US$ Million)
Table 153. Soligenix, Inc. Recent Developments
Table 154. Research Programs/Design for This Report
Table 155. Key Data Information from Secondary Sources
Table 156. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Graft Versus Host Disease Treatment Market Share by Type: 2021 VS 2028
Figure 2. Etanercept Features
Figure 3. Monoclonal Antibodies Features
Figure 4. Thalidomide Features
Figure 5. Tyrosine Kinase Inhibitors Features
Figure 6. mTOR Inhibitors Features
Figure 7. Global Graft Versus Host Disease Treatment Market Share by Application: 2021 VS 2028
Figure 8. Acute GVHD Case Studies
Figure 9. Chronic GVHD Case Studies
Figure 10. Prophylaxis GVHD Case Studies
Figure 11. Graft Versus Host Disease Treatment Report Years Considered
Figure 12. Global Graft Versus Host Disease Treatment Market Size (US$ Million), Year-over-Year: 2017-2028
Figure 13. Global Graft Versus Host Disease Treatment Market Size, (US$ Million), 2017 VS 2021 VS 2028
Figure 14. Global Graft Versus Host Disease Treatment Market Share by Region: 2021 VS 2028
Figure 15. Global Graft Versus Host Disease Treatment Market Share by Players in 2021
Figure 16. Global Top Graft Versus Host Disease Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Graft Versus Host Disease Treatment as of 2021)
Figure 17. The Top 10 and 5 Players Market Share by Graft Versus Host Disease Treatment Revenue in 2021
Figure 18. North America Graft Versus Host Disease Treatment Market Size YoY (2017-2028) & (US$ Million)
Figure 19. North America Graft Versus Host Disease Treatment Market Size Market Share by Type (2017-2028)
Figure 20. North America Graft Versus Host Disease Treatment Market Size Market Share by Application (2017-2028)
Figure 21. North America Graft Versus Host Disease Treatment Market Size Share by Country (2017-2028)
Figure 22. United States Graft Versus Host Disease Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 23. Canada Graft Versus Host Disease Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 24. Europe Graft Versus Host Disease Treatment Market Size YoY (2017-2028) & (US$ Million)
Figure 25. Europe Graft Versus Host Disease Treatment Market Size Market Share by Type (2017-2028)
Figure 26. Europe Graft Versus Host Disease Treatment Market Size Market Share by Application (2017-2028)
Figure 27. Europe Graft Versus Host Disease Treatment Market Size Share by Country (2017-2028)
Figure 28. Germany Graft Versus Host Disease Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 29. France Graft Versus Host Disease Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 30. U.K. Graft Versus Host Disease Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 31. Italy Graft Versus Host Disease Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 32. Russia Graft Versus Host Disease Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 33. Nordic Countries Graft Versus Host Disease Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 34. Asia-Pacific Graft Versus Host Disease Treatment Market Size YoY (2017-2028) & (US$ Million)
Figure 35. Asia Pacific Graft Versus Host Disease Treatment Market Size Market Share by Type (2017-2028)
Figure 36. Asia Pacific Graft Versus Host Disease Treatment Market Size Market Share by Application (2017-2028)
Figure 37. Asia Pacific Graft Versus Host Disease Treatment Market Size Share by Region (2017-2028)
Figure 38. China Graft Versus Host Disease Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 39. Japan Graft Versus Host Disease Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 40. South Korea Graft Versus Host Disease Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 41. Southeast Asia Graft Versus Host Disease Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 42. India Graft Versus Host Disease Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 43. Australia Graft Versus Host Disease Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
List of Figures
Figure 44. Latin America Graft Versus Host Disease Treatment Market Size YoY (2017-2028) & (US$ Million)
Figure 45. Latin America Graft Versus Host Disease Treatment Market Size Market Share by Type (2017-2028)
Figure 46. Latin America Graft Versus Host Disease Treatment Market Size Market Share by Application (2017-2028)
Figure 47. Latin America Graft Versus Host Disease Treatment Market Size Share by Country (2017-2028)
Figure 48. Mexico Graft Versus Host Disease Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 49. Brazil Graft Versus Host Disease Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 50. Middle East & Africa Graft Versus Host Disease Treatment Market Size YoY (2017-2028) & (US$ Million)
Figure 51. Middle East and Africa Graft Versus Host Disease Treatment Market Size Market Share by Type (2017-2028)
Figure 52. Middle East and Africa Graft Versus Host Disease Treatment Market Size Market Share by Application (2017-2028)
Figure 53. Middle East and Africa Graft Versus Host Disease Treatment Market Size Share by Country (2017-2028)
Figure 54. Turkey Graft Versus Host Disease Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 55. Saudi Arabia Graft Versus Host Disease Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 56. UAE Graft Versus Host Disease Treatment Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 57. AbbVie Inc. Revenue Growth Rate in Graft Versus Host Disease Treatment Business (2017-2022)
Figure 58. Acrofan Revenue Growth Rate in Graft Versus Host Disease Treatment Business (2017-2022)
Figure 59. Astellas Pharma Inc. Revenue Growth Rate in Graft Versus Host Disease Treatment Business (2017-2022)
Figure 60. Bristol-Myers Squibb Company Revenue Growth Rate in Graft Versus Host Disease Treatment Business (2017-2022)
Figure 61. ElsaLys Biotech SA Revenue Growth Rate in Graft Versus Host Disease Treatment Business (2017-2022)
Figure 62. F. Hoffmann-La Roche AG Revenue Growth Rate in Graft Versus Host Disease Treatment Business (2017-2022)
Figure 63. Johnson & Johnson Revenue Growth Rate in Graft Versus Host Disease Treatment Business (2017-2022)
Figure 64. Mallinckrodft PLC Revenue Growth Rate in Graft Versus Host Disease Treatment Business (2017-2022)
Figure 65. Merck & Co., Inc. Revenue Growth Rate in Graft Versus Host Disease Treatment Business (2017-2022)
Figure 66. Mesoblast Limited Revenue Growth Rate in Graft Versus Host Disease Treatment Business (2017-2022)
Figure 67. Neovii Biotech GmbH Revenue Growth Rate in Graft Versus Host Disease Treatment Business (2017-2022)
Figure 68. Novartis AG Revenue Growth Rate in Graft Versus Host Disease Treatment Business (2017-2022)
Figure 69. Ocugen, Inc. Revenue Growth Rate in Graft Versus Host Disease Treatment Business (2017-2022)
Figure 70. Pfizer Inc Revenue Growth Rate in Graft Versus Host Disease Treatment Business (2017-2022)
Figure 71. Pluristem Therapeutics Inc. Revenue Growth Rate in Graft Versus Host Disease Treatment Business (2017-2022)
Figure 72. Samedan Ltd Revenue Growth Rate in Graft Versus Host Disease Treatment Business (2017-2022)
Figure 73. Sanofi SA Revenue Growth Rate in Graft Versus Host Disease Treatment Business (2017-2022)
Figure 74. Soligenix, Inc. Revenue Growth Rate in Graft Versus Host Disease Treatment Business (2017-2022)
Figure 75. Bottom-up and Top-down Approaches for This Report
Figure 76. Data Triangulation
Figure 77. Key Executives Interviewed


❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
★リサーチレポート[ 世界の移植片対宿主病治療市場インサイト及び予測（エタネルセプト、モノクローナル抗体、サリドマイド、チロシンキナーゼ阻害剤、mTOR阻害剤）(Global Graft Versus Host Disease Treatment Market Insights, Forecast to 2028)]についてメールでお問い合わせはこちらでお願いします。
◆関連リサーチレポート◆
  • フィラリア症治療のグローバル市場2023年：スプレー薬、服用薬、その他
  • 慢性閉塞性肺疾患治療薬の世界市場見通し2023年-2029年
  • 世界のホスホイノシチド3-キナーゼ阻害剤市場インサイト及び予測（Pan-PI3K阻害剤、デュアルPI3K/mTOR阻害剤、その他）
  • 世界の免疫抑制薬市場インサイト及び予測（カルシニューリン阻害剤、抗増殖剤、mTOR阻害剤、抗体、ステロイド）
  • 世界の免疫抑制剤API市場2022年：コルチコステロイド、ヤヌスキナーゼ阻害剤、カルシニューリン阻害剤、mTOR阻害剤、IMDH阻害剤、生物製剤、モノクローナル抗体